New hope for advanced colon cancer patients out of options
NCT ID NCT03829462
Summary
This study is testing whether adding the chemotherapy drug irinotecan to the targeted drug regorafenib works better than regorafenib alone for people with advanced colorectal cancer that has spread and stopped responding to all standard treatments. It involves 377 participants who have a specific genetic marker (A/A cyclin D1 genotype) and aims to see if the combination helps patients live longer while managing side effects and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRLC Val d'Aurelle-Paul Lamarque
Montpellier, 34298, France
-
Centre Antoine Lacassagne
Nice, Alpes-Maritimes, 06189, France
-
Centre François Baclesse
Caen, Basse-Normandie, 14000, France
-
Centre Léon Bérard
Lyon, Rhône, 69008, France
-
Hôpital Européen Georges Pompidou
Paris, 75015, France
-
Hôpital Pontchaillou
Rennes, Ile Et Vilaine, 35000, France
-
Hôpital Robert Debré
Reims, Marne, 51100, France
-
Hôpital Saint-Jean
Perpignan, Pyrénées-orientales, 66000, France
-
Hôpital privé Jean Mermoz
Lyon, Rhône, 69008, France
-
Institut Godinot
Reims, Marne, 51100, France
-
Institut Gustave Roussy
Villejuif, Val De Marne, 94800, France
Conditions
Explore the condition pages connected to this study.